AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s ...
AstraZeneca has entered an exclusive licence agreement with Alteogen involving the latter’s ALT-B4 platform technology.
AstraZeneca is betting roughly $1.35 billion on Korean biotech Alteogen to help develop under-the-skin versions of multiple ...
Anglo-Swedish pharma major AstraZeneca and Korean biotech Alteogen have entered into an exclusive license agreement for ...
British-Swedish multinational pharmaceutical and biotechnology company AstraZenica on Monday announced the acquisition of ...
AstraZeneca inks license pact with Alteogen for subcutaneous formulations of multiple oncology assets: Cambridge, UK Tuesday, March 18, 2025, 12:00 Hrs [IST] AstraZeneca, a global ...
Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...
Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I ...
HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing ...
Zacks Investment Research on MSN5d
VKTX Inks Manufacturing Deal With CordenPharma for Obesity Drug SupplyViking Therapeutics VKTX signed a broad multi-year manufacturing agreement with CordenPharma, a contract development and ...
Zacks Investment Research on MSN4d
NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With ZealandNovo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 ...
Cambridge: AstraZeneca and Alteogen Inc. have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback